ClinicalTrials.gg
CompletedNCT05679258Updated Jun 28, 2024

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects

A Phase 1 interventional study of HLX15 and US-sourced DARZALEX® in Multiple Myeloma, sponsored by Shanghai Henlius Biotech. Completed at 2 sites in China. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-28.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Enrollment
69th of 406
172 · median 40
Started
2023
with 59 others
Phase 1
151 of 448
73 open now
Registered
223rd of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 69th largest by enrollment of the 406 interventional ones that give a count, is one of 60 that started in 2023, is one of 151 in phase 1, and was the 223rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 60 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX15 with Daratumumab Injection in Healthy Chinese Male Subjects

Read the detailed description

This study contains two parts. Part I of the study is a single-center, randomized, open-label, 2-arm, parallel-controlled phase Ia study to compare the PK characteristics, safety, tolerability, and immunogenicity of HLX15 and daratumumab infusion (DARZALEX®, CN-sourced) in healthy Chinese male subjects.

A total of 24 healthy Chinese male subjects will be enrolled in this part and randomized to the HLX15 group or the CN-sourced DARZALEX® group in a 1:1 ratio, with 12 subjects in each group. The subjects will receive a single dose (8 mg/kg) of HLX15 or CN-sourced DARZALEX® via intravenous infusion.

There is a safety run-in period in the early stage of the study to investigate the safety and tolerability of HLX15 in healthy Chinese male subjects. Another 3-6 subjects will be enrolled to receive the investigational product HLX15 and safety observation will be conducted for 1 week. The Safety Review Committee (SRC) will decide whether to adjust the subsequent study plan based on the safety and tolerability data after administration.

Part II of the study is a multicenter, randomized, double-blind, 3-arm, parallel-controlled phase Ib study to compare similarity of the PK characteristics, safety, tolerability, and immunogenicity of HLX15 and daratumumab infusion (DARZALEX®, US-sourced; DARZALEX®, CN-sourced) in healthy Chinese male subjects.A total of 204 healthy Chinese male subjects are planned to be enrolled in this part and randomly assigned in a 1:1:1 ratio to the HLX15 group, the US-sourced DARZALEX® group, or the CN-sourced DARZALEX® group, with 68 subjects in each group. The subjects will receive a single dose (8 mg/kg) of HLX15, US-sourced DARZALEX®, or CN-sourced DARZALEX® via intravenous infusion.This part may be adjusted according to the results of Part I, including sample size and sampling time points

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • pharmacokinetics
  • CD38
  • multiple myeloma
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years and ≤ 60 years at the time of signing the form (ICF);
  2. Sex: male;
  3. Body weight and (BMI): 18.5 kg/m2 ≤ BMI \< 28 kg/m2; body weight ≥ 55 kg;
  4. The subject should be judged by the physician to be in good general health according to the results of medical history, physical examination, vital signs, examination, laboratory tests, etc. (normal or abnormal without clinical significance);
  5. The subject should be a voluntary participant who has understood and signed the ICF.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who may have diseases that affect their safety or affect the study results, including but not limited to cardiovascular, respiratory, endocrine, metabolic, renal, hepatic, gastrointestinal tract, skin, infection, malignant tumor, hematologic, skeletal, genitourinary, nervous system/ psychiatric or functional disorders, which are judged as by the investigator;
  2. With acute, chronic, or latent infectious diseases within 1 month before administration;
  3. With known immune system diseases ( diseases and immunodeficiency diseases), including but not limited to autoimmune hemolytic anemia;
  4. Has experienced a recent single dermatomal herpes zoster eruption within 6 months before administration;
  5. Has a history of multi-dermatomal herpes zoster or central nervous system (CNS) herpes zoster during the screening period or before;
  6. Positive for indirect antiglobulin test (Indirect Coombs test);
  7. Use of monoclonal antibody, cell therapy, etc. within 6 months before administration, or daratumumab or its analogues or drugs targeting CD38 before administration;
  8. Use of any medication, including prescription drugs, over-the-counter (OTC) drugs, and Chinese herbal medicines, within 2 weeks before administration;
  9. History of drug or food allergy, including allergy to any drug or drug used in the study;
  10. Fear of needles or blood, or difficulty in venous blood collection (history of difficult blood collection or corresponding symptoms and signs, unable to tolerate venipuncture);
  11. History of blood donation or total blood loss of 200 mL or more within 3 months before administration;
  12. Participants in clinical trials of any other drug or device within 3 months (or 5 half-lives of the corresponding product if the half-life of the drug is long (5 half-lives > 3 months)) before administration;
  13. Major surgery within 3 months before signing the ICF;
  14. Positive for virus (HBsAg or HBcAb-positive) antibodies, virus (HCV) antibodies, (HIV), or treponema pallidum antibodies (Anti-TP);
  15. History of drug abuse or substance abuse, or positive in urine drug screening;
  16. Patients who have been vaccinated with attenuated or (such as Bacille Calmette-Guérin, BCG) or viral vector vaccine within 12 months before the first dose, or who plan to be vaccinated with such vaccines within 12 months after administration;
  17. Patients who have been vaccinated with vaccines other than the above attenuated or live viral vaccines and viral vector vaccines within 1 month before the first dose, such as inactivated vaccines and recombinant subunit vaccines;
  18. Male subjects with partners of who have a plan to father a child and/or donate sperm from signing of ICF through 3 months after administration, do not agree to abstain completely from sexual intercourse, or plan to use a method that is not acceptable to the investigator (unacceptable methods of contraception include: i. periodic abstinence \<such as calendar method, ovulation method, basal body temperature method, post-ovulation safety period method, etc.>, withdrawal, etc.; ii. medical contraceptive measures such as oral contraceptives, contraceptive injections, contraceptive patches, subcutaneous implantation, intrauterine hormone contraceptive devices, local contraceptives such as spermicides, etc.);
  19. Subjects with any other conditions that, in the judgment of the investigator, are ineligible for participation in the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    HLX15 group

    Recombinant anti-CD38 fully human monoclonal antibody injection developed by Shanghai Henlius Biotech, Inc.

    Drug: HLX15

  • Active comparator
    US-sourced DARZALEX® group

    Daratumumab injection

    Drug: US-sourced DARZALEX®

  • Active comparator
    CN-sourced DARZALEX® group

    Daratumumab injection

    Drug: CN-sourced DARZALEX®

  • Active comparator
    EU-sourced DARZALEX® group

    Daratumumab injection

    Drug: EU-sourced DARZALEX®

Interventions

  • DrugHLX15

    A single dose (8 mg/kg) of HLX15 via intravenous infusion.

    Also known as: Recombinant anti-CD38 fully humanized monoclonal antibody injection

  • A single dose (8 mg/kg) of US-sourced DARZALEX® via intravenous infusion.

    Also known as: Daratumumab Injection

  • A single dose (8 mg/kg) of CN-sourced DARZALEX® via intravenous infusion.

    Also known as: Daratumumab Injection

  • A single dose (8 mg/kg) of EU-sourced DARZALEX® via intravenous infusion.

    Also known as: Daratumumab Injection

06

What researchers measure

Primary outcomes

  1. Area under the serum concentration-time curve from time 0 to infinity (AUC0-inf).

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 91

Secondary outcomes

  1. Area under the serum concentration-time curve from time 0 to the last measurable concentration (AUC0-t);

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 91

  2. Maximum (peak) serum drug concentration (Cmax);

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 91

  3. Time to reach maximum (peak) serum drug concentration (Tmax);

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 91

  4. Volume of distribution during the terminal phase (Vz);

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 91

  5. Elimination half-life (t1/2);

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 91

  6. Total clearance (CL);

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 91

  7. Percentage of area under serum concentration-time curve obtained by extrapolation (%AUCex).

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 91

Other outcomes

  1. Adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs);

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 91

  2. Number of participants with abnormal vital signs

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 91

  3. Number of participants with abnormal physical examination findings;

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 91

  4. Number of participants with abnormal Laboratory tests results (hematology, serum chemistry, and urinalysis);

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 91

  5. Number of participants with abnormal 12-lead ECG readings.

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 91

  6. Incidence rate of anti-drug antibody (ADA) and NAb

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 91

07

Study locations

2 sites
  • Beijing Hospital
    Beijing, Beijing 100730, China
  • Sir Run Run Hospital, Nanjing Medical University
    Nanjing, Jiangsu 211112, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Mar 2024, 13 months.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 13 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2022
First posted
Jan 10, 2023
StartActual
Jan 31, 2023
Primary completionActual
Mar 16, 2024
CompletionActual
Jun 28, 2024
Last update
Jun 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05679258
Responsible party
Sponsor
First posted
Jan 10, 2023
Start date
Jan 31, 2023
Primary completion
Mar 16, 2024
Completion
Jun 28, 2024
Last update
Jun 28, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion